Skip Navigation LinksHome > March 2014 - Volume 29 - Issue 2 > Aripiprazole augmentation for major depressive disorder: do...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0000000000000012
Short Communications

Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting

Pae, Chi-Una,c; Wang, Sheng-Mina; Han, Changsub; Lee, Soo-Junga; Patkar, Ashwin A.b; Masand, Prakash S.d

Collapse Box


This study investigated the dosing patterns for aripiprazole augmentation for major depressive disorder (MDD) in a naturalistic treatment setting. Between 1 January 2009 and 31 March 2012, patients with a diagnosis of MDD who were receiving aripiprazole augmentation in conjunction with an ongoing antidepressant were recruited for this study. The electronic medical records and clinical data for a total of 276 patients were reviewed up to a year. The mean duration of aripiprazole augmentation was ∼5 months; the mean time to the first increase of aripiprazole was about 3 weeks; and the mean initial, first up-titrated, maximal, and maintenance doses were 3.4, 4.2, 4.7, and 4.4 mg/day, respectively. The most frequent adverse events were insomnia, followed by anxiety and sedation. The current results indicate that the actual doses of aripiprazole augmentation with ongoing antidepressant for MDD should be lower than the doses used in placebo-controlled clinical trials and those recommended by the US Food and Drug Administration. Adequately powered and well-controlled prospective studies are needed to better understand the exact role of low doses of aripiprazole augmentation in the treatment of MDD, particularly in routine practice.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.